A Phase I, Open-label, Dose Escalation and Expansion Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3454 Tablets
Latest Information Update: 04 Jan 2024
At a glance
- Drugs TQB 3454 (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Adverse reactions
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 06 Jan 2022 Planned primary completion date changed from 1 Aug 2021 to 31 Dec 2022.
- 25 Aug 2020 Status changed from not yet recruiting to recruiting.
- 28 Jul 2020 New trial record